Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders
BackgroundsLittle clinical data is available on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with muscular disorders (MDs). The immunogenicity of SARS-CoV-2 vaccines against MDs, in particular, remains unknown. Thus, this study aimed to confirm the immunogenicity and safe...
Main Authors: | Ryousuke Kasai, Michinori Funato, Kanako Maruta, Kunihiko Yasuda, Hiroshi Minatsu, Junji Ito, Kazuhiro Takahashi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1103196/full |
Similar Items
-
Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy
by: Michael Ogundele, et al.
Published: (2021-08-01) -
Intellectual Ability in the Duchenne Muscular Dystrophy and Dystrophin Gene Mutation Location
by: Rasic Milic V., et al.
Published: (2014-12-01) -
Muscular Dystrophy /
by: Naff, Clay Farris, editor 192865, et al.
Published: (2012) -
Comparing the Pain Severity Caused by Muscular Injection of Tramadole in Z and Bulb Methods
by: SH Najafi Doulatabad, et al.
Published: (2008-01-01) -
The Proteome Signatures of Fibroblasts from Patients with Severe, Intermediate and Mild Spinal Muscular Atrophy Show Limited Overlap
by: Sharon J. Brown, et al.
Published: (2022-08-01)